---
subject: Monthly Newsletter Vol.157 - September 2017
---

{{> header-secondary }}

<wrapper class="header header-primary">
	<container>
		<row class="collapse">
			<columns small="12" large="6" valign="middle">
				<img class="logo logo-ddc small-float-center" src="https://blog.drugs.com/wp-content/uploads/2018/02/logo-ddc.jpg" width="211" height="44" alt="Drugs.com">
			</columns>
			<columns small="12" large="6">
				<p class="small-text-center text-right" valign="middle">
					<span class="header-title">Monthly News Roundup</span><br>
					<span class="header-sub-title">Vol 157, September 2017</span>
				</p>
			</columns>
		</row>
	</container>
</wrapper>

<container>
	
	<row>
		<columns small="12">
			<h2>Featured News</h2>
			<p>Lilly's new targeted breast cancer agent, Verzenio, clears the FDA this month, as does GSK's Trelegy Ellipta, a triple drug, once daily inhaler for COPD. Solosec, a single-dose oral treatment for bacterial vaginosis expands new antibiotic options, and Bayer's Aliqopa for relapsed follicular lymphoma joins the booming oncology market. Plus, Amgen's Mvasi is the seventh approved U.S. biosimilar and the first for any cancer indication.</p>
			<center>
				<button href="#" class="radius btn-offset">Read More</button>
			</center>
		</columns>
	</row>

</container>
